Related Posts

Guillain-Barre Syndrome Linked to RSV Vaccine

Pfizer stated in its briefing materials that there may be additional causes for the occurrences. However, it stated that after a prospective approval, a safety study would be conducted to further evaluate Guillain-Barré syndrome

- Advertisement -

According to agency briefing slides released on Friday, the Food and Drug Administration sees a possible risk of Guillain-Barré syndrome with Pfizer’s RSV vaccination for older individuals and has urged the company to conduct a safety study if the injection is approved this spring. According to the FDA filing, two patients in their 60s who received Pfizer’s injection developed Guillain-Barré syndrome out of approximately 20,000 vaccination trial participants.

In the trial’s placebo group — those who did not receive the injection — there were no cases. Guillain-Barre syndrome, also known as inflammatory neuropathy, is a rare condition in which the immune system mistakenly attacks the nerves. The National Institutes of Health list numerous symptoms, including temporary weakness and eventual paralysis. Even in the worst of circumstances, the majority of people recover.

- Advertisement -

Pfizer stated in its briefing materials that there may be additional causes for the occurrences. However, it stated that after a prospective approval, a safety study would be conducted to further evaluate Guillain-Barré syndrome. According to the company, the trial revealed no safety concerns and the vaccination was well received.

Additionally, there may have been a case of Guillain-Barré syndrome in GSK’s RSV vaccination studies, but the company argued there was insufficient evidence to make a diagnosis. According to the FDA, GSK’s safety surveillance plan identifies Guillain-Barré syndrome as a significant potential risk. According to the agency, it will evaluate the strategy and make any necessary recommendations.

The FDA made the briefing materials available the week prior to the advisory committee meetings. Tuesday, the advisors will determine whether the FDA should approve Pfizer’s safety and efficacy findings. They will also vote on the GSK RSV vaccination for senior citizens on Wednesday.

There is no authorised RSV vaccine. Depending on the season, the virus is responsible for between 6,000 and 10,000 deaths per year among the elderly. According to an FDA evaluation of the companies’ data, Pfizer’s vaccination was 85 percent effective at preventing diseases of the lower respiratory tract, while GSK’s vaccination was 83 percent effective.

The Guillain-Barre cases

A 66-year-old American man with a history of hypertension showed symptoms of Guillain-Barré syndrome seven days after receiving the vaccine in Pfizer’s experiment. Prior to the onset of symptoms, the man was admitted to the hospital, underwent an angioplasty, and suffered a heart attack. According to the FDA, the RSV vaccine was not a factor in the heart attack.

Eight days after receiving the vaccination, the man began to experience lower back pain, and fourteen days later, he began to experience weakness in his lower extremities. Following his fall, he was required to return to the hospital, where Guillain-Barré Syndrome was diagnosed. According to the FDA, his symptoms improved after treatment and disappeared six months after first appearing.

A 66-year-old Japanese woman with a history of type 2 diabetes later developed a severe case of Miller-Fisher syndrome, a form of Guillain-Barré syndrome. On the ninth day after vaccination, she felt exhausted, the following day she had a sore throat, and on the tenth day she had poor muscle control. Although she was admitted to the hospital 19 days after the vaccination, all of her symptoms had disappeared three months later.

The FDA stated that it agrees with the investigators’ theory that the incidents may be related to Pfizer’s vaccinations. However, Pfizer stated in its briefing document that additional causes may exist. The company highlighted the man’s heart attack while asserting that his wife exhibited symptoms of an upper respiratory infection.

The FDA stated, however, that Pfizer should consider the cases as a significant potential risk in its safety surveillance, given that the incidence of Guillain-Barré syndrome in the general population is approximately 3 cases per 100,000 people annually. Given the temporal correlation and biological plausibility, the FDA concurred with the investigators’ conclusions that these events may have been related to the study vaccine, the agency stated.

According to an FDA briefing paper, a 78-year-old Japanese woman experienced lower limb weakness nine days after receiving the first dose of the RSV vaccine from GSK. She participated in an open-label study with no placebo-receiving control group. The next day, the woman had difficulty walking, and over the next three days, her upper limb and respiratory muscles began to weaken.

She was hospitalised and treated for Guillain-Barré syndrome. The FDA and the study’s investigator consider the incident to be related to the vaccine. However, GSK stated in its briefing document that a Guillain-Barre diagnosis was not established due to the absence of exam findings and information regarding whether alternative causes were considered. Six months later, the business announced that the patient’s case had been closed.

CDC advisors weigh risks and benefits

The committee of independent vaccine advisors for the Centers for Disease Control and Prevention discussed the three cases of Guillain-Barré syndrome during a public meeting on Thursday. Dr. Michael Melgar, a CDC representative, told the committee that it is difficult to determine whether the cases reflect a genuine safety concern related to the vaccinations or whether they are merely coincidental.

Melgar informed the committee that relative and absolute risk measurements were not estimated “due to the small number of incidents.” However, if the FDA approves the vaccinations, safety monitoring would be crucial, according to a group of doctors and health experts who analysed the data.

According to Melgar, the majority of the workgroup believed that the potential benefits of vaccinations would outweigh any potential risks for those aged 65 and older. Due in part to the occurrences of Guillain-Barré, a minority of individuals believed that the risk-benefit ratio was questionable.

Even though Pfizer and GSK have requested that the FDA approve their respective vaccinations for people aged 60 and older, the CDC panel largely supported a proposal for seniors age 65 and older. This week, no recommendations for the RSV vaccination were presented to the CDC advisory committee for a vote.

According to Dr. Sarah Long, a member of the workgroup, the cases give her pause because if there is evidence linking the vaccine to Guillain-Barre syndrome, seniors may be at a greater risk due to the condition’s increasing prevalence with age. According to Dr. Grace Lee, the leader of the CDC advisory committee, additional information is required because respiratory virus diseases can also cause Guillain-Barre syndrome.

Vaccinations may be able to prevent more cases of Guillain-Barre syndrome by protecting against RSV infection. Lee, associate chief medical officer at Stanford Children’s Health, stated, “You may be preventing more, and we don’t know for sure what the rate is, but I believe that understanding the benefit-risk balance will be incredibly beneficial, at least to me.” “After that, I’ll know if the sixty- and sixty-five-year-olds make sense.”

Popular Articles

We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners. View more
Cookies settings
Privacy & Cookie policy
Privacy & Cookies policy
Cookie name Active
  1. General
  • (1.1.) Eduvast (“Eduvast”, “We”, “Our”, “Us”) is committed to the protection of personal information provided by the users (“You”,“Your”,“User”) to Eduvast. You agree that Your use of Eduvast implies Your consent to the collection, retention and use of Your personal information in accordance with the terms of this Privacy Policy (“Privacy Policy”).
  • (1.2.) We take the privacy of our Users seriously. We are committed to safeguarding the privacy of Users while providing personalized and valuable service.
  • (1.3.) While We do Our best to protect Your information, particularly with respect to the protection of Your personal data, Eduvast cannot ensure the security of Your data transmitted via the internet, telephone or any other networks.
  • (1.4.) Access to the contents available  is conditional upon Your acceptance of this Privacy Policy which should be read together with the End User License Agreement“EULA”.
  • (1.5.) If You do not agree to any of the provisions of this Privacy Policy or EULA, You should not download, install and use the App. We may revise, alter, add, amend or modify this Privacy Policy at any time by updating this privacy policy. By downloading, installing and/or using this App, You agree to be bound by any such alteration, amendment, addition or modification.
2. Information Collected Non Personal Information
  • (2.1.) We may collect non-personal information about You whenever You access or interact with Our Website or any of the related services. This includes but not limited to browser name, version, server location, device specific information such as the type of device used, users’ operating system and version, your mobile devices unique device ID, third party apps or App or service that referred users to App, language preference, means of connection to App, internet service providers, IP address, technical information, google advertising ID (GAID), IDFA, GAID Opt-out Status, location information, interaction of Your device with the App and applications, details of Your device including without limitation its manufacturer details, height and width of your device screen, model, version, UDID or IMEI Number and other similar information about You(collectively "Traffic Data”). Personal Information
  • (2.2.) 2.2. We may collect personal information that identifies You in a variety of ways, including, but not limited to the information submitted during download and installation of the App or in connection with registration for other activities or features offered through the App. Personally identifiable information collected may include name, mailing address, email address, phone number and demographic information such as gender, nationality, postcode and other personal information including but not limited to date, time or place of birth ("Personal Information"). If You communicate with Us by, for example, e-mail or letter, any information provided in such communication may be collected by Eduvast.
  • (2.3.) Our website may transmit your Personal Information to our internal servers. This Personal Information is immediately deleted once you delete the App, except to the extent it is necessary to store the same under applicable laws. Further, we have implemented commercially reasonable physical, managerial, operational and technical security measures to protect the loss, misuse and alteration and to preserve the security of the Personal Information in our care.Finally, this information is used strictly in line with our business purposes.
  • (2.4.) You understand that once You leave Our servers, use of any information You provide shall be governed by the privacy policy of the operator of the site used by You.
3. Disclosure of Personal Information
    • (3.1.) We do not disclose Your Personal Information to any third parties other than as may be required by us, Eduvast’s affiliates, partners, trusted business networks, in compliance with our Privacy Policy for the purpose of moderating the content of the Website, enhancing Your user experience, providing You localised content and to enable Us and Our partners to provide You with targeted information which may be of benefit to you.
    • (3.2.) To enhance customer experience and to provide focused support, we may share generic aggregated demographic information which may include Your information collected by Us but not linked to any personally identifiable information regarding visitors and users with Our business partners, trusted affiliates and advertisers for the purposes outlined above.
    • (3.3.) At times We are required by law or litigation to disclose personal information about the users. We may also disclose information about the user if We determine that disclosure of information is necessary for national security, law enforcement, or other issues of public importance.
    • (3.4.) We use Our best efforts to use information in aggregate form (so that no individual User is identified) for the following purposes:
(3.4.1) To build up marketing profiles; (3.4.2) To aid strategic development, data collection and business analytics; (3.4.3) To manage our relationship with advertisers and partners; (3.4.4) 3.4.4. To audit usage of Our website i.e. (3.4.5) 3.4.5. To enhance user experience in relation to the App and Our website (collectively, “Permitted Use”).
  • (3.5.) We reserve the right to disclose Personal Information if required to do so by law or if we believe that it is necessary to do so to protect and defend the rights, property or personal safety of Eduvast, the App, or Users.
4. Cookies
  • (4.1.) Whenever You access the App We may place "cookies" on Your hard drive for record-keeping purposes to enhance Your experience or sometimes to personalize Your experience. Cookies are small text files that are placed on Your device's hard drive by the App You visit. Cookies help Us to identify information relating Your activities and to retain information relating to Your preferences and history on the App.
  • (4.2.) Ad targeting cookies: We and/or Our service providers may use advertising cookies to deliver ads that are more relevant to You and Your interests.
  • (4.3.) You may choose to disable cookies by turning off cookie feature on the web browser. However, by disabling this feature, some parts of the App may not function properly. This may prevent You from taking full advantage of the App.
5. Confidentiality
    • (5.1.) Except as otherwise provided in this Privacy Policy, We will keep Your Personal Information private and will not share it with third parties, unless We believe in good faith that disclosure of Your Personal Information or any other information We collect about You is necessary for Permitted Use or to:
(5.1.1.) Comply with a court order or other legal process; (5.1.2.) Protect the rights, property or safety of Eduvast or another party; (5.1.3.) Enforce the Agreement, including EULA; or (5.1.4.) Respond to claims that any posting or other content violates the rights of third-parties. 6. Security
  • (6.1.) The security of Your Personal Information is important to Us. We follow generally accepted industry standards to protect the Personal Information submitted to Us, both during transmission and once We receive it.
  • (6.2.) Although We make best possible efforts to store Personal Information in a secure operating environment which is not open to the public, You should understand that there is no such thing as complete security, and We do not guarantee that there will be no unintended disclosures of Your Personal Information. If We become aware that Your Personal Information has been disclosed in a manner not in accordance with this Privacy Policy, We will use reasonable efforts to notify You of the nature and extent of such disclosure (to the extent We know that information) as soon as reasonably possible and as permitted by law.
7. Updates and Changes to Privacy Policy
  • We reserve the right, at any time, to add to, change, update, or modify this Privacy Policy so please review it frequently. In all cases, use of information We collect is subject to the Privacy Policy in effect at the time such information is collected. You hereby acknowledge and agree that it is Your responsibility to review this Privacy Policy periodically and become aware of the modifications. If You disagree to any of the changes to the Privacy Policy, You shall refrain from using or accessing the App. Your continued use of the App following the posting of the revised Policy shall indicate Your acceptance and acknowledgment of the changes and You will be bound by it.
8. Updates and Changes to Your Personal Information
  • You have a right to correct any errors in Your Personal Information available with Us. You may request Us in writing that We cease to use Your Personal Information.
9. Contact Us
  • You may write to us at [email protected] for any privacy concerns and requests relating to this EULA and Privacy Policy.
Save settings
Cookies settings